Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity profiling

Article metrics


Protein ubiquitination is a post-translational modification (PTM) that regulates various aspects of protein function by different mechanisms. Characterization of ubiquitination has lagged behind that of smaller PTMs, such as phosphorylation, largely because of the difficulty of isolating and identifying peptides derived from the ubiquitinated portion of proteins. To address this issue, we generated a monoclonal antibody that enriches for peptides containing lysine residues modified by diglycine, an adduct left at sites of ubiquitination after trypsin digestion. We use mass spectrometry to identify 374 diglycine-modified lysines on 236 ubiquitinated proteins from HEK293 cells, including 80 proteins containing multiple sites of ubiquitination. Seventy-two percent of these proteins and 92% of the ubiquitination sites do not appear to have been reported previously. Ubiquitin remnant profiling of the multi-ubiquitinated proteins proliferating cell nuclear antigen (PCNA) and tubulin α-1A reveals differential regulation of ubiquitination at specific sites by microtubule inhibitors, demonstrating the effectiveness of our method to characterize the dynamics of lysine ubiquitination.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Generation of monoclonal antibodies that selectively recognize diglycine-modified lysines.
Figure 2: Profiling immunopurified ubiquitin remnant–containing peptides to identify ubiquitinated proteins.
Figure 3: Bioinformatic analysis of ubiquitinated proteins and ubiquitin-modified lysines.
Figure 4: Colchicine differentially regulates the ubiquitination of two lysines in PCNA.

Accession codes




  1. 1

    Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425–479 (1998).

  2. 2

    Xu, P. & Peng, J. Dissecting the ubiquitin pathway by mass spectrometry. Biochim. Biophys. Acta 1764, 1940–1947 (2006).

  3. 3

    Ericsson, C., Goldknopf, I.L. & Daneholt, B. Inhibition of transcription does not affect the total amount of ubiquitinated histone 2A in chromatin. Exp. Cell Res. 167, 127–134 (1986).

  4. 4

    Galluzzi, L., Paiardini, M., Lecomte, M.C. & Magnani, M. Identification of the main ubiquitination site in human erythroid alpha-spectrin. FEBS Lett. 489, 254–258 (2001).

  5. 5

    Tomlinson, E., Palaniyappan, N., Tooth, D. & Layfield, R. Methods for the purification of ubiquitinated proteins. Proteomics 7, 1016–1022 (2007).

  6. 6

    Beers, E.P. & Callis, J. Utility of polyhistidine-tagged ubiquitin in the purification of ubiquitin-protein conjugates and as an affinity ligand for the purification of ubiquitin-specific hydrolases. J. Biol. Chem. 268, 21645–21649 (1993).

  7. 7

    Peng, J. et al. A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21, 921–926 (2003).

  8. 8

    Srikumar, T., Jeram, S.M., Lam, H. & Raught, B. A ubiquitin and ubiquitin-like protein spectral library. Proteomics 10, 337–342 (2010).

  9. 9

    Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 258, 8206–8214 (1983).

  10. 10

    Denis, N.J., Vasilescu, J., Lambert, J.P., Smith, J.C. & Figeys, D. Tryptic digestion of ubiquitin standards reveals an improved strategy for identifying ubiquitinated proteins by mass spectrometry. Proteomics 7, 868–874 (2007).

  11. 11

    Rechsteiner, M. Ubiquitin-mediated pathways for intracellular proteolysis. Annu. Rev. Cell Biol. 3, 1–30 (1987).

  12. 12

    Bonifacino, J.S. & Weissman, A.M. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu. Rev. Cell Dev. Biol. 14, 19–57 (1998).

  13. 13

    Kirkpatrick, D.S., Denison, C. & Gygi, S.P. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat. Cell Biol. 7, 750–757 (2005).

  14. 14

    Sun, L. & Chen, Z.J. The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 16, 119–126 (2004).

  15. 15

    Etlinger, J.D., Li, S.X., Guo, G.G. & Li, N. Phosphorylation and ubiquitination of the 26S proteasome complex. Enzyme Protein 47, 325–329 (1993).

  16. 16

    Peters, J.M. Subunits and substrates of the anaphase-promoting complex. Exp. Cell Res. 248, 339–349 (1999).

  17. 17

    Schwartz, D. & Gygi, S.P. An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat. Biotechnol. 23, 1391–1398 (2005).

  18. 18

    Ahmad, S. & Gromiha, M.M. NETASA: neural network based prediction of solvent accessibility. Bioinformatics 18, 819–824 (2002).

  19. 19

    Catic, A., Collins, C., Church, G.M. & Ploegh, H.L. Preferred in vivo ubiquitination sites. Bioinformatics 20, 3302–3307 (2004).

  20. 20

    Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).

  21. 21

    Gnad, F. et al. PHOSIDA (phosphorylation site database): management, structural and evolutionary investigation, and prediction of phosphosites. Genome Biol. 8, R250 (2007).

  22. 22

    Kim, S.C. et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607–618 (2006).

  23. 23

    Zhao, S. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010).

  24. 24

    Basu, A. et al. Proteome-wide prediction of acetylation substrates. Proc. Natl. Acad. Sci. USA 106, 13785–13790 (2009).

  25. 25

    Yang, X.J. & Seto, E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31, 449–461 (2008).

  26. 26

    Prosperi, E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Prog. Cell Cycle Res. 3, 193–210 (1997).

  27. 27

    Mayer, A. et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71, 2454–2460 (1993).

  28. 28

    Ong, S.E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376–386 (2002).

  29. 29

    Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2, 1–17 (2002).

  30. 30

    Wisniewski, J.R. et al. Constitutive and dynamic phosphorylation and acetylation sites on NUCKS, a hypermodified nuclear protein, studied by quantitative proteomics. Proteins 73, 710–718 (2008).

  31. 31

    Gigant, B. et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435, 519–522 (2005).

  32. 32

    Ravelli, R.B. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198–202 (2004).

  33. 33

    Unk, I. et al. Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. USA 103, 18107–18112 (2006).

  34. 34

    Derrien, D. et al. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj. J. 6, 241–255 (1989).

  35. 35

    Kirkpatrick, D.S., Weldon, S.F., Tsaprailis, G., Liebler, D.C. & Gandolfi, A.J. Proteomic identification of ubiquitinated proteins from human cells expressing His-tagged ubiquitin. Proteomics 5, 2104–2111 (2005).

  36. 36

    Xu, P. et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137, 133–145 (2009).

  37. 37

    Shevchenko, A., Wilm, M., Vorm, O. & Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850–858 (1996).

  38. 38

    de Godoy, L.M. et al. Status of complete proteome analysis by mass spectrometry: SILAC labeled yeast as a model system. Genome Biol. 7, R50 (2006).

  39. 39

    Xu, G., Shin, S.B. & Jaffrey, S.R. Global profiling of protease cleavage sites by chemoselective labeling of protein N-termini. Proc. Natl. Acad. Sci. USA 106, 19310–19315 (2009).

  40. 40

    Elias, J.E. & Gygi, S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207–214 (2007).

  41. 41

    Silva, J.C. et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal. Chem. 77, 2187–2200 (2005).

  42. 42

    Mortensen, P. et al. MSQuant, an open source platform for mass spectrometry-based quantitative proteomics. J. Proteome Res. 9, 393–403 (2010).

  43. 43

    Thomas, P.D. et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003).

  44. 44

    Dennis, G. Jr. et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4, 3 (2003).

  45. 45

    Lu, Z. et al. Predicting subcellular localization of proteins using machine-learned classifiers. Bioinformatics 20, 547–556 (2004).

  46. 46

    Rosner, J. Test of auditory analysis skills (TAAS) in helping children overcome learning difficulties: a step-by-step guide for parents and teachers (Academic Therapy, New York, 1979).

  47. 47

    Kabsch, W. & Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577–2637 (1983).

  48. 48

    Linding, R. et al. Protein disorder prediction: implications for structural proteomics. Structure 11, 1453–1459 (2003).

  49. 49

    Hubbard, S.J., Campbell, S.F. & Thornton, J.M. Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors. J. Mol. Biol. 220, 507–530 (1991).

Download references


We thank T. Neubert and G. Zhang (New York University) for useful suggestions, P. Zhou (Weill Cornell Medical College, WCMC) for the His6-ubiquitin plasmid, U. Hengst, A. Deglincerti, R. Almeida and B. Derakhshan for the assistance during initial cell culturing, S. Gross and Y. Ma (WCMC Mass Spectrometry Core Facility) for helpful discussion in MS/MS analysis, F. Campagne, L. Skrabanek, J. Sun (WCMC Institute for Computational Biomedicine) for instructions and assistance in bioinformatic analysis. The mass spectrometry work was performed at the WCMC Mass Spectrometry Core Facility using instrumentation supported by US National Institutes of Health (NIH) RR19355 and RR22615. This work was supported by grants from Weill Cornell, NIH (MH086128) (S.R.J.), and a pharmacology cancer training grant from the National Cancer Institute (T32CA062948) (G.X. and J.S.P.).

Author information

S.R.J. and G.X. conceived and designed the study. G.X. and J.S.P. conducted the experiments, and G.X. and S.R.J. analyzed the data. S.R.J. and G.X. wrote the manuscript.

Correspondence to Samie R Jaffrey.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1 and 2 and Supplementary Figs. 1–18 (PDF 12207 kb)

Rights and permissions

Reprints and Permissions

About this article

Further reading